CADL
Candel Therapeutics, Inc.
$8.35
+7.19%
2026-05-08
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Key Fundamentals
Forward P/E
-12.17
EPS (TTM)
$-0.72
ROE
-64.6%
Profit Margin
0.0%
Debt/Equity
94.44
Price/Book
8.23
Beta
-0.58
Market Cap
$570.8M
Avg Volume (10D)
1.7M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$8.36
60D Low
$4.44
Avg Volume
1.6M
Latest Close
$8.35
Get breakout alerts for CADL
Sign up for Breakout Scanner to receive daily notifications when CADL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Candel Therapeutics, Inc. (CADL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CADL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CADL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.